| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.21 | 4e-07 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.24 | 2e-06 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-06 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.22 | 1e-05 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.23 | 1e-05 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.19 | 2e-05 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-05 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.14 | 9e-05 |